Are you familiar with the stock MGRX (MangoSciences)? If you’re studying to discover new stocks, you’ll want to put them in your watchlist. Investor sentiment is changing. We’re moving from pessimism to a bullish outlook. Federal Reserve futures on the Chicago Mercantile Exchange (CME) show that inflation has fallen to near the Fed’s target range, indicating that the central bank is preparing for its final rate hike.
Emerging Small-Cap Opportunities! Mango Scientifics (MGRX)
The entire market is experiencing a new bull market, but the average investor hasn’t realized it yet. That’s why we think it’s a good time to look for new growth opportunities in lesser-known small-cap stocks. There are some interesting small-cap stocks that are gaining momentum in the market while trading below $2 per share on the Nasdaq. That’s Mangoceuticals, Inc. (NASDAQ ticker: MGRX).
In the men’s health and wellness segment, the company is expected to register an impressive CAGR of 15.00% through 2029. The company has a unique position in its market and is rapidly gaining brand recognition, but the stock market has yet to take notice.
Growth potential and innovative products
Much of the company’s growth can be attributed to marketing and brand exposure efforts over the past few months. The CEO has appeared on CNBC, Fox Business, Bloomberg TV, and other outlets to promote the company and become a major sponsor.
MGRX is also leading a national movement for men’s health and wellness in conjunction with other marketing efforts, launching a dedicated website and a “Make America Hard Again” campaign (a play on the political slogan, “Make America Great Again”) to build brand awareness for the product.
The company just had an IPO on the Nasdaq, and its stock price has been going up and down, only recently stabilizing. It went public at $4 on March 22, 2023, and now it’s less than $2. This is common enough that I think it makes sense to look at the future or fundamentals rather than price action. The company reportedly made $5 million from the IPO anyway. This led to investment. So we’re expanding our core product line and growing our market share.
Unlike our competitors who offer generic erectile dysfunction treatments, MangoSciences prides itself on offering a unique and safe combination of compounds. Made with FDA-approved ingredients, Mango combines a variety of compounds to address the problems men face (?).
It’s an inherently market-disruptive model. Original Mango is a specialty medicine that contains the same active ingredient as Cialis™ (tadalafil), plus other FDA-approved ingredients to maximize effectiveness. Packaged as a fast-acting tablet that is absorbed by mouth, it works within 15 minutes and lasts up to 36 hours.
A few weeks ago, we announced that we would soon be launching our second Mango ED product, utilizing an existing custom compound alongside the active ingredient in Viagra™ (sildenafil). These are fast-acting mango-flavored tablets that activate and dissolve in the mouth for immediate action, just like the original.
Own prescriptive platform is also a plus
Another interesting thing the company has going for it is its unique telemedicine platform.
You need a prescription to get access to mangoes. However, the company has built a telehealth infrastructure to facilitate this process. Once the individual completes the online telehealth visit, MGRX’s network of healthcare providers reviews the prescription and, if medically appropriate, approves the prescription and ships the product to the customer immediately.
In conclusion, it can be said that MGRX has a best-in-class product that delivers faster results without the hassles typically experienced by emergency room patients. It’s a cheap Nasdaq small cap with a disruptive angle on a $31 billion market that’s currently growing at a 15% compound annual rate. It’s a unique strategy that’s garnering quite a bit of attention. That’s why it’s worth taking a closer look at MGRX at the start of a new bull market.
- This post referenced the links below.
Source link
